[{"id":"15ea0b15-7362-42f9-a5c9-83b6fa5b6dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451982","created_at":"2021-01-18T11:45:29.420Z","updated_at":"2025-02-25T14:35:37.102Z","phase":"Phase 2","brief_title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT02451982","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • PD-1 • TNFRSF9 • GZMB • IL17A","pipe":"","alterations":" ","tags":["CD8 • PD-1 • TNFRSF9 • GZMB • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous • urelumab (BMS-663513)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-06"}]